Tamsulosin is a selective α1 receptor antagonist.Target: α1 receptorTamsulosin is a selective α1 receptor antagonist that has preferential selectivity for the α1A receptor in the prostate versus the α1B receptor in the blood vessels. Tamsulosin-treated patients had a 0.30-fold lower risk of developing acute urinary retention compared with control patients. None of the International Continence Society male questionnaire domain scores showed significant changes between the groups [1]. tamsulosin can be recommended for treating men after catheterization for AUR, and can reduce the likelihood of the need for re-catheterization [2].

[1]. Jeong, I.G., et al., Impact of tamsulosin on urinary retention following early catheter removal after robot-assisted laparoscopic radical prostatectomy: a prospective randomized controlled trial. Int J Urol, 2014. 21(2): p. 164-8. [2]. Lucas, M.G., T.P. Stephenson, and V. Nargund, Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int, 2005. 95(3): p. 354-7.